Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moEPLERENONE (eplerenone) by Viatris (2) is aldosterone antagonists [moa]. Approved for hypertension, to lower blood pressure, survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (hfref) after an acute myocardial infarction (mi) and 3 more indications. First approved in 2023.
Drug data last refreshed 22h ago
Aldosterone Antagonists
Aldosterone Antagonist
Worked on EPLERENONE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.
Pharmacokinetics Study of Eplerenone Coated Tablets
Pharmacokinetics of Eplerenone Tablet
Cardiometabolic Effects of Eplerenone in HIV Infection
Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo